APM
CSTL icon

Avidity Partners Management’s Castle Biosciences CSTL Stock Holding History

Avidity Partners Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-150,000
Closed -$10.1M – 105
2020
Q4 		$10.1M Buy
+150,000
New +$8.13M 0.33% 66

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $691M AUM 27.96% 1-Year Est. Return

Avidity Partners Management's CSTL Position: Q1 2021 in Review

Avidity Partners Management sold out of Castle Biosciences (CSTL) in Q1 2021, closing a stake of 150,000 shares — an estimated $10.1M sold.

Avidity Partners Management first reported a position in CSTL in Q4 2020 and held it in 1 quarter. The position peaked at $10.1M in Q4 2020. 175 funds tracked by Wall St. Rank hold CSTL as of Q1 2021.

  • Avidity Partners Management reported no remaining Castle Biosciences position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 150,000 Castle Biosciences shares in Q1 2021, an estimated $10.1M.
  • Avidity Partners Management first reported a position in Castle Biosciences in Q4 2020 and held it in 1 quarter.
  • Avidity Partners Management's Castle Biosciences position peaked at $10.1M in Q4 2020.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.